Log In
BCIQ
Print this Print this
 

Inhaled xenon

  Manage Alerts
Collapse Summary General Information
Company NeuroproteXeon Inc.
DescriptionInhaled xenon
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationCognitive dysfunction
Indication DetailsPrevent ischemic white matter damage in comatose out-of-hospital cardiac arrest patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today